Please use this identifier to cite or link to this item:
|Title:||Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents|
|Authors:||HERNANDEZ Reinier; HESKAMP Sandra; RIJPKEMA Mark; BOS Desirée L.; GOLDENBERG David; MCBRIDE William; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; CAI Weibo; BOERMAN Otto|
|Citation:||THERANOSTICS vol. 7 no. 1 p. 1-8|
|Publisher:||IVYSPRING INT PUBL|
|Type:||Articles in periodicals and books|
|Abstract:||Despite the large interest on nuclear/optical multimodality imaging, the effect of radiation on the fluorescence of fluorophores remains unexplored. Herein we determined the radiosensitivity of two near infrared fluorescent compounds, IRDye 800CW (800CW) and a dual modality imaging tetrapeptide containing DOTA as chelator and Dylight 800 as fluorophore, exposed to increasing activities of 111In, 68Ga, or 213Bi (γ, β, and α emitter, respectively). An activity and type of radiation-dependent radiation-induced loss of fluorescence, radiobleaching, of 800CW was observed upon incubation with escalating activities of 111In, 68Ga, or 213Bi. 68Ga showed the largest radiolytic effect, followed by 111In and 213Bi. The addition of oxygen radical scavengers including ethanol, gentisic acid, and ascorbic acid (AA), provided a concentration dependent radioprotective effect. These results supported the hypothesis of a free radical-mediated radiobleaching mechanism. AA provided the most robust radioprotection over a wide range of concentrations and preserved fluorescence at much higher radioactivity levels. Overall, both fluorescent compounds displayed similar sensitivity, except for 213Bi-irradiated solutions, where the dual modality construct exhibited enhanced radiolysis, presumably due to direct radiation damage from α particles. Concurrently, AA was not able to preserve fluorescence of the dual-modality molecule labeled with 213Bi. Herein we report on the radiobleaching of fluorophores, and describe conditions to provide robust radioprotection under practical (pre)clinical conditions. Our recommendations have strong repercussions for the preparation of dual-modality radiopharmaceuticals.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.